Quotes 5-day view Delayed Nasdaq
01/20/2021
01/21/2021
01/22/2021
01/25/2021
01/26/2021
Date
125.14(c)
132.98(c)
131.02(c)
147(c)
152.88
Last
8 001 568
20 880 838
10 067 191
26 970 870
13 645 635
Volume
+0.10%
+6.26%
-1.47%
+12.20%
+4.00%
Change
Sales 2020
512 M
-
-
Net income 2020
-571 M
-
-
Net cash position 2020
2 597 M
-
-
P/E ratio 2020
-120x
Yield 2020
-
Sales 2021
9 689 M
-
-
Net income 2021
5 144 M
-
-
Net cash position 2021
9 212 M
-
-
P/E ratio 2021
12,0x
Yield 2021
-
Capitalization
58 169 M
58 169 M
-
EV / Sales 2020
109x
EV / Sales 2021
5,05x
Nbr of Employees
1 100
Free-Float
90,0%
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows:
- Collaboration revenue (79.8%);
- Grant revenue (20.2%).
At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and...
Notations Surperformance© of Moderna, Inc.
Trading Rating :
Investor Rating :
All news about MODERNA, INC.
News in other languages on MODERNA, INC.
Analyst Recommendations on MODERNA, INC.
MODERNA, INC. - 2020
The beginning of the move
BUY
Stocks lag, dollar advances on COVID-19 concerns
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MODERNA, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
16
Average target price
137,93 $
Last Close Price
147,00 $
Spread / Highest target
25,9%
Spread / Average Target
-6,17%
Spread / Lowest Target
-53,1%
Please enable JavaScript in your browser's settings to use dynamic charts.